Loading…
Cellectis S.A.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CLLS.
▼ -86.3% over 5Y.
today you would have $116.57▼ -88.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $4.84 | $1.80 | $3.08 | $2.10 | |
| P/S | 5.8x | 6.7x | 3.1x | 292.7x | 5.0x |
| P/B | 1.8x | 6.4x | 1.0x | 2.6x | 0.8x |
| EPS | -$0.67 | -$0.41 | -$1.77 | -$2.33 | |
| Profit margin | -323.15% | -92.66% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ADCTADC Therapeutics SA | $1.23 | — | — | — | — | $157.03M |
| OTLKOutlook Therapeutics, Inc. | $0.64 | — | — | — | — | $156.5M |
| BNRBurning Rock Biotech Ltd | $15.08 | — | 2.2x | — | -12.82% | $158.99M |
| LFMDLifeMD, Inc. | $3.30 |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Company description provided by Yahoo Finance.
| -88.57% |
| -13385.30% |
| -553.64% |
| ROE | -89.51% | -89.05% | -28.05% | -119.32% | -89.97% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 19.8x |
| — |
| -515.90% |
| $159.06M |
| KZIAKazia Therapeutics Ltd | $13.58 | — | 4.6x | — | -106.90% | $155.18M |
| NRXPNRX Pharmaceuticals, Inc. | $3.55 | — | — | — | — | $153.7M |